Zwitterionic Polymer For Drug Delivery Applications by Lu, Yang
Wayne State University
Wayne State University Dissertations
1-1-2018
Zwitterionic Polymer For Drug Delivery
Applications
Yang Lu
Wayne State University,
Follow this and additional works at: https://digitalcommons.wayne.edu/oa_dissertations
Part of the Chemical Engineering Commons
This Open Access Embargo is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in Wayne
State University Dissertations by an authorized administrator of DigitalCommons@WayneState.
Recommended Citation
Lu, Yang, "Zwitterionic Polymer For Drug Delivery Applications" (2018). Wayne State University Dissertations. 2046.
https://digitalcommons.wayne.edu/oa_dissertations/2046
ZWITTERIONIC POLYMER FOR DRUG DELIVERY APPLICATIONS 
by 
YANG LU 
DISSERTATION 
Submitted to the Graduate School 
of Wayne State University, 
Detroit, Michigan 
in partial fulfillment of the requirements  
for the degree of  
DOCTOR OF PHILOSOPHY 
2018 
MAJOR: CHEMICAL ENGINEERING 
Approved By: 
 
Advisor                                            Date 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© COPYRIGHT BY 
YANG LU 
2018 
All Rights Reserved
 
 
ii 
 
ACKNOWLEDGMENTS 
At first, I would like to express my sincere gratitude to my advisor Prof Zhiqiang Cao for 
the continuous support of my Ph.D. study and research, for his encouragement, motivation, and 
many tips both on research and personal careers. His guidance helped me to improve myself to 
know how to dedicate to research and increase working efficiency. During the past 5 years, he 
always teaches me how to be a researcher and helped me to overcome obstacles. It’s hard for me 
to reach the requirement of Ph.D. graduate without his help and guidance. 
In addition, I would like to thank all other thesis committee members: Prof. Haipeng Liu, 
Prof. Matthew Allen, and Prof. Steven Salley, for their attending, supporting and insightful 
advice. 
I would also like to thank my fellow labmates: Dr. Wei Wang, Hui Zhu, Dr. Ershuai Zhang, 
Dr. Jianhai Yang, Dr. Hong Du, Xiangfei Han and Hanyu Jia, for the insightful discussion, for 
the time working together and their kind help on my research study.  
Last, I would like to thank my parents, for giving birth to me at the first place and 
supporting me throughout my life. 
  
 
 
 
 
 
 
 
 
 
iii 
 
TABLE OF CONTENTS 
 
Acknowledgments ........................................................................................................................................ ii 
LIST OF TABLES ........................................................................................................................................ v 
LIST OF FIGURES ..................................................................................................................................... vi 
Chapter 1. Introduction ................................................................................................................................. 1 
Chapter 2. Discovery of Ultra-low CMC Zwitterionic Micelles .................................................................. 6 
2.1 Introduction ......................................................................................................................................... 6 
2.2 Materials and Methods ........................................................................................................................ 8 
2.2.1 Material ........................................................................................................................................ 8 
2.2.2 Preparation of gold nanoparticles (NPs) encapsulated by DSPE-PCB 5K .................................. 8 
2.3 Results and Discussion ........................................................................................................................ 9 
Chapter 3 Therapeutic Performance of drug/DSPE-PCB 5K formulation ................................................. 31 
3.1 Introduction ....................................................................................................................................... 31 
3.2 Materials and Methods ...................................................................................................................... 32 
3.2.1 Materials .................................................................................................................................... 32 
3.2.2 Preparation of docetaxel/DSPE-PCB 5K formulation ............................................................... 32 
3.2.3 Animal Experiments .................................................................................................................. 33 
3.3 Results and Discussion ...................................................................................................................... 35 
Chapter 4. Simple protein modification using zwitterionic polymer .......................................................... 46 
4.1 Introduction ....................................................................................................................................... 46 
4.2 Materials and Methods ...................................................................................................................... 47 
4.2.1 Materials .................................................................................................................................... 47 
4.2.2 Synthesis of PCB-(N-hydroxysuccinimide) (NHS) ................................................................... 48 
4.2.3 Synthesis of PCB-insulin and PEG-insulin ................................................................................ 48 
4.2.4 Purification of PCB-insulin and PEG-insulin ............................................................................ 49 
 
 
iv 
 
4.2.5 Other Characterization ............................................................................................................... 49 
4.2.6 Animal Experiments .................................................................................................................. 50 
4.3 Results and Discussion ...................................................................................................................... 51 
Chapter 5. Conclusion ................................................................................................................................. 63 
Abstract ....................................................................................................................................................... 69 
Autobiographical statement ........................................................................................................................ 70 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
v 
 
LIST OF TABLES 
 
Table 4-1 The relative area under the curve (AUC) and elimination half-life (t1/2) of native 
insulin and its conjugates in blood serum. Data are illustrated by average ± standard deviation, 
n=6…...…………………………………………………………………………………………. 59 
Table 4-2 The secondary structure proportion of insulin samples measured from Circular 
Dichroism (CD) Spectroscopy……………………………………………………….…………. 61 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vi 
 
LIST OF FIGURES 
Figure 2-1. Ultra-low-CMC micelles and their unusual ability to stabilize cargoes in extremely 
diluted conditions with micelle concentrations far below CMCs of common micelles.  
Conventional micelles dissociate at a concentration below CMC, and thus cannot stabilize a 
hydrophobic cargo. Structure for ultra-low-CMC micelles is shown. For conventional micelles, 
their polar groups were either non-ionic (e.g., Polysorbate 80, having hydrophobic nature), or 
only contained one ionic group (e.g., sodium dodecyl sulfate). Sharp-contrast micelles with 
multiple polar zwitterionic (polyzwitterionic) groups were recently reported. …………..…17 
Figure 2-2. TEM and DLS data of DSPE-PCB 5K micelle. a, Representative TEM image for 
DSPE-PCB 5K micelle (5 mM) in water taken by JEOL 2010 Transmission electron microscopy. 
Stained with 2% uranyl acetate. The scale bar in the figure is 50 nm. b, DLS data for DSPE-PCB 
5K in PBS (0.5 mM), showing an average diameter of 20 ± 3.5 nm (mean ± SD, N = 3) with a 
polydispersity index of 0.13………………...………………………………………...………….18 
Figure 2-3. The hydrophobic core domains of DSPE-PCB 5K micelle were detected using 
pyrene as reflected by the decrease in the intensity ratio of the first to the third highest energy 
bands (I1/I3) in the emission spectra of pyrene from 1.7 in water (a) to 1.16 in 0.17 mg/ml micelle 
in water (b). The excitation wavelength was 334 nm ……………………………………...18 
Figure 2-4. The CMC of DSPE-PCB 5K was determined to be 1.3 x 10-3 mM using the pyrene 
probe method (mean ± SD, N=3) …………………………………...………………….………19 
Figure 2-5. “Diluting-concentrating” method to probe CMCs for micelles. Aggregation of the 
gold probe at different micelle concentrations was reflected by a, hydrodynamic size of the 
colloid and b, gold maximum absorbance wavelength (mean ± SD, N=3). Dashed arrow in both 
figures indicate the CMC values. CMC data for DSPE-PEG are from reference. CMC data for 
other commercial available micelles are provided by the manufacturer……………...…….… 20 
Figure 2-6. “Diluting-concentrating” method to determine micelle CMCs using gold NP as a 
probe. Measuring curves for all samples tested are shown (a-j), including non-ionic, cationic, 
anionic, and zwitterionic surfactants. Aggregation of the gold probe at different micelle 
concentrations was reflected by the hydrodynamic size of the colloid and gold maximum 
absorbance wavelength (mean ± SD, N=3). Known CMC values for micelles were listed and 
indicated by dashed arrows. The current “diluting-concentrating” method is able to detect a CMC 
as low as 2.7 x 10-6 mM. ……………………………………………………………………….25 
Figure 2-7. CaCO3 probes were encapsulated in DSPE-PCB 5K micelle, by dissolving micelles 
and CaCl2 in 10 ml deionized water followed by dropwise addition of 1 ml Na2CO3 aqueous 
solution under vigorous stirring at room temperature for 15 min (micelle:CaCl2:Na2CO3 (molar 
ratio) = 1:1:1). (a) The size of DSPE-PCB 5K/CaCO3 nanoparticles before dilution. Micelle 
concentration was 3 mg/mL (0.5 mM), and CaCO3 concentration was 0.05 mg/mL (0.5 mM). (b) 
The size of DSPE-PCB 5K/CaCO3 nanoparticles after 1000-fold dilution to micelle 
 
 
vii 
 
concentration of 5 x 10-7 M, and CaCO3 concentration of 0.05mg/L, and then concentrated back 
to the original concentration at (a). The solubility of CaCO3 in water is 0.013 g/L or 13 mg/L. 
The concentration of CaCO3 encapsulated in micelle before dilution (0.05 mg/mL) was above its 
solubility (0.013 mg/mL), and the concentration of CaCO3 encapsulated in micelle after dilution 
(0.05 mg/L) was below its solubility (13mg/L). CaCO3 was found to be released at diluted 
concentration and aggregated into large particles after condensation as shown at (b)……….….26 
Figure 2-8. TEM figures of DSPE-PCB 5K micelle at an extremely low concentration (2.7×10-6 
mM). Stained with 2% uranyl acetate. The scale bar in the figure is 20 nm. …………….....…. 26 
Figure 2-9. Effect of supplying zwitterionic moieties decreases CMCs of conventional micelles, 
and the impact of zwitterionic PCB MW on the CMC of DSPE-PCB. a,b, Gold NPs were loaded 
in SDS(a) and Polysorbate 80 (b), respectively, and upon water dilution, their aggregation 
behavior (due to micelle dissociation) was measured by the increase in maximum absorbance 
peak of gold (mean ± SD, N=3). When 500 mg/mL CB was used as dilution solvent, no 
significant gold NP aggregation was observed in the dilution range, indicating a significantly 
stabilized micelle (despite a concentration below its inherent CMC). In contrast, when 500 
mg/ml OEG was used as dilution solvent, there was gold NPs aggregation at high micelle 
concentrations, showing an increase of micelle CMC. CB and OEG alone (without the aid of 
micelles) cannot stabilize gold NPs, leading to severe aggregation. It should be noted that DLS 
data are not reliable in this experiment since the large concentration of small-sized CB or OEG 
moieties interferes with the hydrodynamic size readings for aggregated gold NPs. c, d, “Diluting-
concentrating” method to probe CMCs for DSPE-PCB 2K, 5K, 10K micelles. Aggregation of the 
gold probe at different micelle concentrations was reflected by the gold maximum absorbance 
wavelength (c) (mean ± SD, N=3) and the hydrodynamic size of the colloid (d) (mean ± SD, 
N=3). CMC values were determined for DSPE-PCB 2K and 10K are indicated by dashed 
arrows…………………………………….....................................................................................27 
Figure 2-10. Gold NPs were loaded in SDS (a) and Polysorbate 80 (b) respectively, and upon 
water dilution, their aggregation behavior (due to micelle disassociation) was measured by the 
increase in maximum absorbance peak of gold (mean ± SD, N=3). When 100 mg/mL PCB 
polymer (MW= 5K) was used as dilution solvent, no gold nanoparticle aggregation was observed 
in the dilution range, indicating micelle were stabilized even at a concentration below its inherent 
CMC. In contrast, when 100 mg/mL PEG polymer (MW= 5K) was used as dilution solvent, 
there was gold NP aggregation at concentrations above it inherent CMC of micelles. PCB and 
PEG alone (without the aid of micelles) cannot stabilize gold NPs, leading to severe aggregation. 
It should be noted that DLS data are not reliable in this experiment since the presence of a large 
concentration of small size PCB or PEG interferes with the hydrodynamic size reading for the 
aggregated gold NPs. Different concentration of PCB solutions was used as dilution solvent, and 
within the concentration series, 40 mg/mL PCB was the minimum required to stabilize (c) SDS 
and (d) Polysorbate 80 upon dilution (mean ± SD, N=3). Different concentration of CB solutions 
were used as dilution solvents, and within the concentration series 200 mg/mL CB was the 
minimum required to stabilize (e) SDS and (f) Polysorbate 80 upon dilution (mean ± SD, 
N=3). ……………………………………………….………………………...…………….….29 
 
 
viii 
 
Figure 2-11. Stability of ultra-low-CMC micelle and conventional micelles with gold NP probes 
encapsulated at 5.5 × 10-2 mM micelle concentration in 100% fetal bovine serum (FBS) over 72 
h at room temperature. Potential micelle disassociation resulted in gold NPs aggregation, which 
was measured by gold maximum absorbance peak (mean ± SD, N=3). Known CMC values for 
each micelle are indicated inside the graph. …………………………......……………..……… 29 
Figure 3-1. Stability of different docetaxel formulation diluted in FBS (mean ± SD, N=3). ..... 38 
Figure 3-2. The release profile of different docetaxel formulations in the dialysis tube against 
PBS. (mean ± SD, N=3) ……………………………….………………………………...………38 
Figure 3-3. Stability of different docetaxel formulations as reflected by the hydrodynamic size of 
the formulation before and after lyophilization (mean ± SD, N = 3). The circles in each bar 
represent an original data point…………………………………………………………………..39 
Figure 3-4.  Dose escalation in healthy mice. Solutions of different formulations a, Taxotere; b, 
docetaxel/DSPE-PCB; c, docetaxel/DSPE-PEG; d, docetaxel/Polysorbate 80 were administered 
through intravenous tail vein injection. (mean ± SD, N=3). …………………………………….41 
Figure 3-5. (a)Anti-tumor performance of docetaxel/DSPE-PCB 5K formulation (mean ± SD, N 
= 7) compared with other formulations (mean ± SD, N = 7). On day 10 after treatment (*), a 
Mann-Whitney Test indicated that docetaxel/DSPE-PCB 5K delayed the tumor growth greater 
than all other four controls at p = 0.005 (b), Survival rate curves of mice treated with the 
different formulations. (c), Probability of cure. In mice bearing invisible tumors < 1mm3 in size 
or a flattened and darkened scar tissue developed, it was considered that the tumor had been 
completely eradiated. Line represent docetaxel/DSPE-PEG 5K, docetaxel/polysorbate 80, 
taxotere and PBS are overlapped………………………………………………………………...42 
Figure 3-6. The concentration of docetaxel in blood plasma of different formulations (mean ± 
SD, N = 4). …………………………………………………………………………………...... 43 
Figure 3-7. Bio-distribution of different docetaxel formulations at 24 hours post i.v. injection 
(mean ± SD, N= 4). One-Way ANOVA analysis with Bonferroni multi-comparison: significant 
difference between docetaxel/DSPE-PCB 5K and docetaxel/DSPE-PEG 5K, docetaxel/DSPE-
PCB 5K and docetaxel/Polysorbate 80, docetaxel/DSPE-PCB 5K and Taxotere, at p < 0.001 
(***), p < 0.0001 (****), and p < 0.0001 (****), respectively. ...…...………………………….44 
Figure 3-8. Bio-distribution of different docetaxel formulations. a, bio-distribution of docetaxel 
from different formulations at 2 hours post i.v. injection (mean ± SD, N= 4). One-Way ANOVA 
analysis with Bonferroni multi-comparison: significant difference between docetaxel/DSPE-PCB 
5K and docetaxel/Polysorbate 80, docetaxel/DSPE-PCB 5K and Taxotere, at p < 0.01 and p < 
0.05, respectively. No significant difference between docetaxel/DSPE -PCB 5K and 
docetaxel/DSPE-PEG 5K. b, bio-distribution of docetaxel from different formulations at 8 hours 
post i.v. injection (mean ± SD, N= 4). One-Way ANOVA analysis with Bonferroni multi-
 
 
ix 
 
comparison: significant difference between docetaxel/DSPE-PCB 5K and docetaxel/DSPE-PEG 
5K, docetaxel/DSPE-PCB 5K and docetaxel/Polysorbate 80, docetaxel/DSPE-PCB 5K and 
Taxotere, at p < 0.01, p < 0.0001, and p < 0.001, respectively………………………………....44 
Figure 4-1. (a) The schematic illustration of PCB conjugation with native recombinant human 
insulin. There are three amino acids with free amino groups (GlyA1, PheB1, and Lys B29) that 
are available for PCB conjugation. The disulfide bonds in insulin were labeled with yellow sticks.  
(b) MALDI-TOF Mass spectra of native insulin, PEG-insulin, and PCB-insulin. …….…..……58 
Fig. 4-2 (a) Hydrodynamic sizes for free insulin, PEG-insulin, and PCB-insulin, respectively, as 
measured by DLS. Samples were dissolved in 0.2 M pH8.4 HEPES buffer. (b) The serum insulin 
concentration as a function of time after the tail vein injection of free insulin, PEG-insulin, and 
PCB-insulin, respectively. The data are presented as the percentage of the initial values of serum 
insulin concentration over time ± standard deviation (n=6). ………………..…………….….... 59 
Fig. 4-3 (A) Circular dichroism (CD) spectra of native insulin, PEG-insulin, and PCB-insulin 
(0.2 mg/mL insulin or conjugates at 0.2 M pH8.2 PBS buffer), respectively. (B) The bioactivity 
of native insulin, rough PEG-insulin, purified PEG-insulin, rough PCB-insulin, and purified 
PCB-insulin, respectively, as measured by phosphorylation of the insulin receptor in vitro. The 
relative activity was presented as the percentage relative to native insulin ± standard deviation 
(n=6). *p < 0.05, **p < 0.01, n.s.=not significant. The relative blood glucose concentration as a 
function of time after the tail vein injection of free insulin, PEG-insulin, and PCB-insulin (C) 
before and (D) after purifying insulin conjugate products. The data are presented as the 
percentage of the initial values of blood glucose concentration ± standard deviation 
(n=6).……………...………………………………………………………………….….…….... 60 
Figure 4-4: MALDI-TOF Mass spectra of native insulin, purified PEG-insulin and purified 
PCB-insulin where most of the three amines of insulin were conjugated with PEG or 
PCB. ………………………………………………………………………………………….… 61 
Figure 4-5: (A) The bioactivity of native insulin, rough PEG-insulin, purified PEG-insulin, 
rough PCB-insulin and purified PCB-insulin, respectively, as measured by phosphorylation of 
the insulin receptor in vitro.  For the polymer-insulin tested, most of the three amines of insulin 
were conjugated with PEG or PCB.  The relative activity was presented as the percentage of 
native insulin (n=6). *** p < 0.001. (B) The relative blood glucose concentration as a function of 
time after the tail vein injection of free insulin, rough PEG-insulin, and rough PCB-insulin 
(before purifying insulin conjugate products). The data are presented as the percentage of the 
initial values of blood glucose concentration ± standard deviation (n=6) ………………………62 
 
1 
 
 
 
CHAPTER 1. INTRODUCTION 
Zwitterionic polymers are a unique type of polymers having an equivalent number of 
homogenously distributed anionic and cationic groups on their polymer chains[1]. Common 
zwitterionic polymers include poly(betaine) or poly(choline) carrying a positive and a negative 
charge on the same monomer unit such as 2-methacryloyloxylethyl phosphorylcholine (MPC)[2], 
sulfobetaine methacrylate (SBMA)[3], and carboxybetaine methacrylate (CBMA)[4]. There are 
also a series of zwitterionic-like polymers prepared by copolymerization of monomers with 
positive and negative charges at the ratio of 1:1 (For example, the monomers can be selected 
from charged natural amino acids[5]), showing a similar property of zwitterionic materials[6]. The 
highly soluble and neutral zwitterionic materials are known to provide strong hydration through 
ionic solvation, forming a molecular level water layer to resist nonspecific binding and 
attachment from proteins, blood, cells, and bacteria[7]. Such distinctive resistance is known as 
non-fouling property, which is desirable in many scientific areas[8]. 
Based on the super-hydrophilic and non-fouling property of zwitterionic materials, they 
have been widely involved to render excellent stealth properties to a variety of substrates of 
different geometries, including decorating nano-sized carbon dots[9], and coating a flat 
macroscopic surface, to resist protein binding and bacteria attachment[10]. The use of zwitterionic 
materials for biological and medical applications has been considered promising. Recent studies 
indicated that there was negligible foreign body reaction after implanting a zwitterionic 
poly(carboxybetaine methacrylate) (PCBMA) hydrogel into the mice subcutaneously[11]. 
PCBMA hydrogel surface was also demonstrated to retain the stem cell phenotype and 
multipotency, regardless the existence of differentiation-promoting media and cytoskeletal-
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manipulation agents[12]. This remarkable performance in interacting with host tissues or cells has 
been attributed to the non-fouling nature of the zwitterionic materials.  
The focus of this thesis is to explore two additional properties of these super-hydrophilic 
zwitterionic polymers and take advantage of these properties in solving several challenges in the 
drug delivery field.  
(1) Capability to stabilize micelles constructed with zwitterionic polymers. 
In the last decades, polymeric micelles have attracted considerable interest as drug delivery 
carrier for a series of drugs, including low molecular mass hydrophobic drugs, proteins and 
genes[13]. Typically, micelles would self-assemble into the macromolecular structure in an 
aqueous environment and protect insoluble hydrophobic payloads in its hydrophobic core region. 
Compared with other drug delivery strategies, such as liposomes, polymer or protein-drug 
conjugates, polymeric nanoparticles, or pathogens[14], polymeric micelles show two significant 
advantages: 1) Micelles have relatively small size. Hydrodynamic sizes of a micelle are usually 
less than 50 nm[15]. Considering the dimensions of physiological pores in the body’s vasculatures 
(e.g., kidney glomerulus pores, inter-endothelial junctions for healthy tissues, tumors, and 
cancerous tissues), nanomedicine of smaller sizes (e.g., < 100 nm) is favored in blood circulation, 
tissue penetration, and cellular uptake[16]. Recent evidence shows a sub-50 nm drug formulation 
is desirable to achieve the collective outcome of deeper tumor tissue penetration and more 
efficient cancer cell internalization, as well as a cellular response[14l, 17]. Therefore, in vivo 
circulation performance of encapsulated drugs could be drastically improved, leading to high 
accumulation in the targeted site (e.g., tumor tissue) due to the enhanced permeability and 
retention (EPR) effect[18]. 2) Feasibility to manufacture in large scale. Typically, the micelle is 
the simplest assembled entity, with well-defined molecular structures and assembling behaviors. 
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Such simple strucutre enables simple drug formulation and ease of manufacturing. Such 
feasibility is vital since other advanced particle systems are complicated to prepare and have 
built up obstacles for production in a stable and consistent manner. One notable example is the 
PEGylated liposome with encapsulated doxorubicin (DOXIL®), which used to have a periodic 
global shortage due to manufacturing issues[19]. In contrast, a micelle formulation is simple to 
manufacture, such as Taxotere® or Taxol®, containing only the drug (docetaxel), the micelle 
(polysorbate 80), and the solvent(alcohol);[20] can obtain fast FDA-approval; and be easily 
manufactured on a large scale. With these appealing features, micelles are well accepted as a first 
line technology to formulate drugs[13a]. Nevertheless, a fundamental limitation for micelles as 
drug delivery carriers is their low stability to environmental changes, especially their 
spontaneous dissociation at relatively low concentration. Once the concentration is below their 
critical micelle concentration (CMC), micelle entities would disassociate into free surfactant and 
cause a burst release of previously encapsulated drugs into the bloodstream. For example, 
micellar drug Taxotere® was quickly removed from blood circulation once intravenously(i.v.) 
injected[21]. This quick clearence can reduce the therapeutic performance of encapsulated drugs 
and even cause toxicity concern[22]. Therefore, how to stabilize micelles, especially in 
physiological conditions, is a challenge for drug delivery application.   
In this dissertation, it is reported that zwitterionic Poly(carboxybetaine) (PCB) polymer 
could conjugate with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) lipid to form a 
micelle with ultra-low CMC. A novel method was proposed to verify its ultra-low CMC and the 
high stability in different media were also studied. The mechanism for zwitterionic PCB to 
achieve ultra-low CMC property has been preliminarily explored. Details are described in 
Chapter 2. Using melanoma as a tumor model, the antitumor performance of docetaxel 
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encapsulated in DSPE-PCB micelle is described in Chapter 3 where enhanced antitumor 
performance compared with control formulations, including the commercial Taxotere®, was 
observed. 
(2) Capability to improve the pharmacokinetics of proteins while mitigating the commonly 
seen bioactivity loss. 
Therapeutic protein drugs, such as insulin, have been used clinically for a long time. Using 
polymers to modify a protein drug could effectively increase its circulating half-life in the 
bloodstream, reduce the dosage required, and improved the therapeutic performance-- a 
significant advantage for patients. Polymer-protein conjugation has been extensively explored in 
the past decades and has shown the enhanced stability of the protein under storage, transport, and 
other stresses[23]. For example, protein stability under lyophilization is significantly increased 
after modification with polymers.[24] The most widely used conjugation strategy is called 
PEGylation, by using polyethylene glycol (PEG) to conjugate proteins.[25] However, a major 
problem with PEGylation, as well as conjugating with other common polymers, is the sacrificed 
bioactivity of the conjugated protein.[26] Significant results indicate that conjugating PEG, and 
other polymers as well, on proteins through conventional covalent coupling chemistry resulted in 
polymer chains non-selectively attached on the protein surface groups (e.g., amines), and 
potential attachment near to the protein’s active site significantly inhibited the protein from 
performing designated biological function (e.g., amine group on Gly A1 of insulin)[27]. A much 
higher dosage was required to reach the same therapeutic effect for the protein-drug with reduced 
bioactivity and significantly compromised pharmacological activity. Compared with unmodified 
native form, polymers modified protein drugs may demand high production costs and cause 
long-term toxicity concerns due to the drastically increased working dose. We discovered that 
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zwitterionic PCB-polymer-modified insulin did not show a significant reduction (student t-test) 
of in vitro bioactivity compared with its native form. By improving the pharmacokinetics of 
insulin while maintaining its bioactivity, PCB-insulin was found to show even higher blood 
glucose lowering capability compared with native insulin in an animal study. PCB-insulin was 
obtained via a simple conventional coupling chemistry and was expected to solve the bioactivity 
loss issue in large. Details are described in Chapter 4.  
Copyrights of texts and figures in this dissertation related to my publications were obtained 
through copyright t© Spring Nature 2018 and copyright © John Wiley and Sons 2017. 
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CHAPTER 2. DISCOVERY OF ULTRA-LOW CMC ZWITTERIONIC 
MICELLES 
A fundamental challenge for conventional micellar carriers is micelle systems disassemble 
into free surfactants when diluted at concentrations below the critical micelle concentration 
(CMC). Such premature disassemble limits the bioavailability in vivo of injected hydrophobic 
drugs encapsulated in micellar systems. In this chapter, a novel micelle comprising a 
superhydrophilic zwitterionic polymer domain and a superhydrophobic lipid domain is 
introduced. Such a micelle was demonstrated to own an undetectable CMC below 10-6 mM, a 
value that is orders of magnitude lower than the CMC (> 10-3 mM) of typical micellar systems. 
In addition, when zwitterionic moieties or zwitterionic polymers were added into a micelle 
solution, conventional micelle could be stabilized even at a concentration below their inherent 
CMC. 
2.1 Introduction 
Micelles play a pivotal role in drug delivery[15, 22a, 28]. They are small sub-50 nm entities 
physically assembled by water-soluble amphiphilic surfactants and can solubilize hydrophobic 
drug molecules that are not well dissolved in water. Compared with other drug stabilizing or 
delivery strategies (including from liposomes, polymer- or protein-drug conjugates and 
polymeric nanospheres to cells or pathogens)[14a-k, 14m, 14n, 29], micelles have been received as the 
first-line technology.[22a] Their molecular structures and assembling behaviors are well defined, 
and a drug solution stabilized by micelles can be easily manufactured. These features enables 
large scale production and stable clinical performance of the formulations. However, the main 
challenge with micelles is that all conventional micelles, unless chemically crosslinked,[13b, 15, 22a, 
28a] will disassemble into free surfactants under diluted conditions (e.g., below critical micelle 
concentrations, CMC, which is typical when infusing the micelle/drug formulation into the body). 
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Drugs previously stabilized in the hydrophobic region of a micelle core will become insoluble 
due to the loss of micelle structure. Such precipitation will severely reduce its bioavailability and 
deteriorate its therapeutic performance.[22, 30] This challenge remained insurmountable since all 
micelles have an apparent CMC and cannot keep stabilizing hydrophobic cargo when diluted at 
concentrations below the CMC.[28b] 
In this chapter, it is demonstrated that such stability challenge could be potentially solved 
by a so-called “sharp polarity contrast” micelle system (Fig. 2-1). In this sharp contrast system, 
each surfactant molecule comprises a super-hydrophilic zwitterionic polymer domain and a 
superhydrophobic lipid domain. The polarity contrast between the two domains is drastically 
“sharper” than most conventional micelle molecules. With an appropriate molecular weight 
(MW) of zwitterionic polymers, such sharp-contrast micelles have an undetectable ultra-low 
CMC below 2.7 x 10-6 mM. Such ultralow CMC for micelle is at least six orders of magnitude 
lower than that for sodium dodecyl sulfate (SDS, CMC = 8.2 mM; commonly found in cleaning 
and hygiene products) and four orders of magnitude lower than Polysorbate 80 (CMC = 0.012 
mM; widely used to formulate drugs, e.g., chemo drug docetaxel under the trade name of 
TAXOTERE®[31]). Even when a zwitterionic moiety or polymer was added into a micelle 
solution (not chemically modifying the micelle), the existing micelle molecules in the new 
solution were stabilized at concentrations below their inherent CMC. It is demonstrated that the 
ultra-low CMC micelle could stabilize hydrophobic cargoes (without micelle dissociation) in 
extremely diluted conditions (for example, < 10-3 mM), including clinically relevant dilution 
conditions in serum in which conventional micelles failed to stabilize hydrophobic cargoes.  
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2.2 Materials and Methods 
2.2.1 Material 
DSPE-PCB 2K, 5K, and 10K were synthesized and characterized following a previously 
established method.[32] The molecular weight of N-hydroxysuccinimide ester (NHS)-PCB was 
characterized via Waters Breeze 2 system gel permeation chromatography (GPC) with Waters 
2414 reflex detector. The mobile phase was phosphate buffered saline (PBS) at a flow rate of 1 
mL/min. Polysorbate 80, SDS, CTAB, HAuCl4, NaBH4, styrene, divinylbenzene, 
trifluoroethanol were obtained from Sigma-Aldrich. (St. Louis, USA). DSPE-PEG 5K was 
obtained from Laysan Bio, Inc. (Arab, USA). Hexadecyltrimethylammonium bromide (CTAB), 
(dodecyl dimethylglycine) CB12C, n-Tetradecyl-N, N-Dimethylglycine (CB14C), 3-
(decyldimethylammonio) propane sulfonate (SB10C) and 3-(N, N-Dimethylpalmitylammonio) 
propane sulfonate (SB16C) were obtained from Anatrace Product. LLC (Maumee, USA).   
2.2.2 Preparation of gold nanoparticles (NPs) encapsulated by DSPE-PCB 5K 
CMC for DSPE-PCB 5K (a zwitterionic carboxy betaine polymer (PCB) of 5000 Dalton 
molecular weight (MW) conjugated to 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) 
lipid) was determined via an established pyrene method.[33] During a typical “Diluting-
concentrating” method for CMC determination, a probe (< 5 nm) is first loaded into a micelle 
core at high micelle concentration (> CMC). To load gold nanoparticle (NP) probe, micelles and 
HAuCl4 are dissolved in 10 mL deionized water and vigorously stirred at room temperature, 
followed by dropwise addition of 1 mL NaBH4 aqueous solution (micelle: Au: NaBH4 (molar 
ratio) is typically 1:1:6). The solution turns red, and the stirring is kept for another 5 min. To 
load cross-linked Polystyrene NP probe, micelles, photo-initiator 2959 (2-hydroxy-4'-(2-
hydroxyethoxy)-2-methyl-propiophe), styrene and divinyl benzene (molar ratio is typically 
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1:10:1.5:1) are sonicated in deionized water to form nano-emulsion, followed by 20 min reaction 
under UV light (365 nm). Micelles with either gold NP or PS NP loaded are further purified 
through 10K MWCO ultrafiltration to remove rough materials forming the probes, and 0.2 μm 
filter to remove unexpected large particles. The size of the probes can be determined by DLS 
(Zetasizer Nano-ZS, Malvern Instruments) by taking the size difference between empty micelles 
and loaded micelles. For gold NPs probe, its size can be additionally measured by the maximum 
absorbance wavelength using a UV-visible spectrometer (Thermo Scientific Multiscan Go). 
During the diluting-concentrating procedure for CMC determination, the liquid sample was not 
further treated with filtration.  
Aggregation Numbers (Nagg) of DSPE-PCB 5K micelles were calculated from the ratio of 
an apparent molecular mass of the micelles which was measured via static light scattering (SLS), 
and Mw for a single DSPE-PCB 5K chain. Apparent molecular masses of DSPE-PCB 5K 
micelles was obtained by measuring a series of samples with different concentrations (from 1.2 
g/L to 4.8 mg/L) using a Malvern Zetasizer Nano-ZS.  
2.3 Results and Discussion 
Sharp-contrast micelle-forming molecule DSPE-PCB 5K was synthesized following a 
previous method,[32] and its structure is shown in Fig. 2-1 DSPE-PCB 5K powder is extremely 
water-soluble, and its resulting micelles were imaged by transmission electron microscopy (TEM) 
(Fig. 2-2a). The size of this micelle was measured by dynamic light scattering (DLS) (Fig. 2-2b) 
to have a hydrodynamic diameter of 20±3.5 nm (mean ± stand deviation, N=3) in phosphate -
buffered saline (PBS). The hydrophobic core domain of DSPE-PCB 5K micelle was detected 
using pyrene as reflected by the decrease in the intensity ratio of the first to the third highest 
energy bands (I1/I3) in the emission spectra of pyrene from 1.7 in water to 1.1 in micelle solution 
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(Fig. 2-3), following a previous method.[33] It should be noted that PCB such as 5K Dalton 
molecule weight is extremely water soluble without forming particles or aggregates 
(hydrodynamic diameter =3.7±1.0 nm). The aggregation number (Nagg) of DSPE-PCB 5K 
micelle in water was 44. 
The CMC for DSPE-PCB 5K was determined to be 1.3 x 10-3 mM using the pyrene probe 
method (Fig. 2-4).[33] The pyrene method is one of the most sensitive and precise methods of 
CMC determination.[34] However, it does not have sufficient sensitivity to measure a CMC below 
10-3 mM[35] because the final concentration for pyrene is maintained at 6 x10-4 mM (in our 
previous protocol as well as others[33, 36]) to give good quality fluorescent spectra. A micelle 
concentration approaching or below 10-4 mM cannot significantly change the aggregation 
behavior of pyrene, and potential micelle formation cannot be detected (as reflected by pyrene 
spectrum change). As a consequence, 1.3 x10-3 mM as measured by the pyrene method is an 
upper CMC estimation for DSPE-PCB 5K. There are other fluorescent dyes such as 2-p-
toluidinylnaphthalene-6-sulfonate (TNS) and 1-anilinonaphthalene-8-sulfonate (ANS),[37] or 
other ways to determine CMC including light and X-ray scattering,[38] surface tension study,[39] 
and isothermal titration calorimetry.[40] None of those methods can precisely detect a CMC < 10-4 
mM. Limited success in determining a CMC < 10-4 mM has been achieved by extrapolation of 
CMC values of structurally-similar molecules[41] and through filtration of radioactively labeled 
surfactants.[42] However, these approaches are not readily available. 
To explore a potential CMC below 10-3 mM, a “diluting-concentrating” method was 
developed. An initial stable colloid was prepared by reducing soluble Au3+ ions to insoluble gold 
nanoparticles (NPs) in the presence of micelles at concentrations far above their CMCs. Small 
gold NPs (< 5 nm) were formed as non-soluble probes and partitioned into the hydrophobic cores 
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of stabilized micelles. The gold probe size was estimated from maximum absorbance peak of 
gold NPs,[43] and also from the size increase from empty micelle to probe-loaded micelle 
(measured by DLS). The micelle-protected gold NPs were subject to serial dilutions in water, 
and extremely diluted micelle concentrations (10-6 mM) can be reached. Potential aggregation of 
gold NPs resulted in an increase in both the hydrodynamic size of the colloid and the maximum 
absorbance wavelength for gold NPs,[43] as measured by DLS and UV-spectroscopy, respectively. 
Considering that the samples may be too dilute for these measurements, they were concentrated 
using a rotary evaporator at 35 oC under reduced pressure and then re-measured for these 
parameters. The aggregation of hydrophobic gold NPs cannot be reversed by this concentrating 
process and was detected from their corresponding concentrated samples. Generally, once 
hydrophobic gold NPs aggregated, they cannot be re-dispersed to their original size and size-
distribution, even with sonication. There is a possibility that DSPE-PCB 5K may be unique from 
all the other surfactants in that it is capable of re-stabilizing the aggregated gold NPs upon 
concentration. This possibility is excluded based on the following experiment: A polysorbate 80 
protected gold NPs solution at micelle concentration of 2.1 mM had an initial hydrodynamic size 
of 20.5 ± 3.2 nm (size of gold NPs). Then the solution was diluted with water to reach micelle 
concentration of 0.0042 mM. To this solution, DSPE-PCB 5K was added to reach the 
concentration of 0.0042 mM. The mixture was then condensed to the polysorbate 80 
concentration of 2.1 mM which is above its CMC. If DSPE-PCB 5K could re-stabilizing the 
aggregated gold NPs upon concentration, the size of gold nanoparticle after concentration should 
be similar to the size before dilution. However, size of gold nanoparticle in this concentrated 
mixture was measured to be 68.3 ± 7.5 nm, indicating that the previously aggregated gold NPs 
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did not re-disperse. So DSPE-PCB 5K is not unique to re-stabilizing the aggregated gold NPs 
upon concentration. 
Since cargo aggregation is attributed to the dissociation of protecting micelles, this method 
indirectly detects CMC values. A series of common micelles commercially available with known 
CMCs labeled by the manufacturers were used to verify this method, including non-ionic 
micelles (polysorbate 80, DSPE-PEG 5K and 2K), cationic micelles 
(hexadecyltrimethylammonium bromide (CTAB)), anionic micelles (sodium dodecyl sulfate 
(SDS)), zwitterionic carboxy betaine and sulfobetaine micelles with varied hydrophobic chain 
lengths (dodecyl dimethylglycine (CB12C), N-Tetradecyl-N-N-Dimethylglycine (CB14C), 3-
(decyldimethylammonio) propane sulfonate (SB10C), 3-(N,N-
Dimethylpalmitylammonio)propane sulfonate (SB16C)). Representative measuring curves are 
shown in Fig.2-5. Measuring curves for all samples tested are shown in Fig. 2-6. Without 
exception, CMC values for all micelles are right positioned at a concentration, below which both 
the hydrodynamic size of the colloid and the maximum absorbance wavelength for gold NPs 
start to increase significantly (Student’s t-test, p < 0.05). Similar to common probes for CMC 
determination (for example, pyrene and other dye molecules and so on.), the presence of gold 
NPs in the hydrophobic micelle core does not seem to influence the dissociation behavior of 
micelles. If it did, an artefact signifying that the colloid system does not aggregate below the 
CMC would appear. 
DSPE-PCB 5K has an undetectable ultra-low CMC. Using the validated “diluting-
concentrating” method, DSPE-PCB 5K micelle protected gold NPs do not show signs of cargo 
aggregation at a concentration as low as to 2.7 x 10-6 mM (Fig. 2-5; no significant signal increase 
based on Student’s t-test). Their CMC is considered ultra-low and below our current detection 
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limit of 2.7 x 10-6 mM. The detection limit can potentially be lowered by one order of magnitude 
by further diluting the micelles (for example, into a 10 L container), then concentrating 1.0 -1.5 
L each time (using the current 2 L evaporation flask). This approach is laborsome and has little 
room to further lower the CMC detection limit. In contrast, DSPE-PEG 5K micelles, widely used 
to construct nanomedicines, have an apparent CMC about 1 x 10-3 mM, consistent with literature 
values[35, 44], and dissociate at concentrations, at least, three orders of magnitude higher than 
DSPE-PCB 5K. Compared with DSPE-PCB 5K, which has multiple zwitterionic  CB moieties as 
the polar group, CB14C contains only one zwitterionic carboxy betaine and has higher CMC at 
3.4 x 10-2 mM. To confirm that DSPE-PCB 5K has an ultra-low CMC, following experiments 
were performed: 1) Gold NP colloids were formed in the presence of PCB 5K replacing DSPE-
PCB 5K and were found to be unstable (aggregate). Note that DSPE-PCB 5K/gold colloid was 
stable at room temperature for weeks without precipitation. This control experiments excludes 
the possibility of PCB tightly interacting with gold NPs, preventing dissociation of DSPE-PCB 
5K micelles (an artifact of lowered CMC). 2) Gold NP probes were replaced by cross-linked 
polystyrene (PS) NP probes. Following the same “diluting-concentrating” method, where colloid 
aggregation was detected by DLS, CMC results were obtained similarly to Fig. 2-5a, regardless 
of the probe used (Fig. 2-6). It should be noted that both gold and crosslinked PS NPs are not 
soluble under extremely diluted conditions (10-6 mM). This insoluble property is the key to 
obtaining reliable CMC results. Soluble salt NPs (e.g., CaCO3) were not found to work as probes 
since they are released from the micelle at a diluted concentration below their water solubility 
and aggregated when concentrated to the concentration above their water solubility (Fig. 2-7). 3) 
DSPE-PCB 5K micelles at an extremely low concentration (2.7 x 10-6 mM) have been observed 
using TEM (Fig 2-8).   
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Zwitterionic PCB and its amount are critical to achieving ultra-low CMC property. 
To explore the unique role of zwitterionic PCB in contributing to ultra-low CMC property,  
conventional micelles (i.e., SDS and Polysorbate 80) were incubated either the free form of the 
CB moiety or PCB 5K (with multiple CB) at high concentration (500 mg/mL for free form 
carboxybetaine moiety and 80 mg/mL PCB) and found that conventional micelles were 
stabilized in both cases (Fig. 2-9a, b and Fig. 2-10a, b). It should be noted that similar 
stabilizing effects have been found in both inorganic and organic salt solutions.[45] We attribute 
this effect to the super-hydrophilicity of CB and PCB (similar to salts), which increases the 
polarity of the aqueous phase,[32, 46] strengthens the hydrophobic-hydrophobic interactions and 
drives micelle assembly at concentrations far below inherent CMC. The presence of ethylene 
glycol oligomer (OEG) or polymer (PEG), in contrast, increased the CMC for conventional 
micelles (Fig. 2-9a, b and Fig. 2-10a, b), which is consistent with the literature.[47] OEG and 
PEG are known for their hydrophobic nature and tend to decrease the polarity of the aqueous 
environment,[32, 46] behaving the opposite to super hydrophilic CB and PCB. OEG and PEG are 
typical water-soluble materials, and in some cases, their hydrophobic nature has been overlooked. 
They should be strictly considered as amphiphilic materials since they can be dissolved in both 
water and organic solvents such as dichloromethane. Zwitterionic polymers, by contrast, can be 
dissolved in water but can be hardly dissolved in most organic solvents and are generally 
considered to be superhydrophilic. Because of the polarity difference, PEG and zwitterionic 
polymers have shown opposite effects such as in stabilizing lipid membrane[48], and avoiding 
interaction with protein active center so as to reduce bioactivity loss of polymer-protein 
conjugates[49]. The micelle stabilizing effect of CB or PCB 5K at a series of concentrations were 
further examined. It was found that a minimum of roughly 200 mg/mL CB and 40 mg/mL PCB 
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5K were required to prevent the dissociation of conventional micelles, e.g., SDS and Polysorbate 
80 (Fig. 2-10c, d, e, f). Thus, the presence of zwitterionic CB moieties as polar groups for 
DSPE-PCB 5K appears to be the key to the ultra-low CMC property.  
In addition, it was found that an appropriate molecular weight (MW) of PCB (amount of 
CB moieties per polymer) is critical for DSPE-PCB to achieve the lowest possible CMC (Fig. 2-
9c, d). PCB MW is expected to be as high as possible to ensure the CMC lowering effect. 
However, PCB MW should not be too large since micelles with longer hydrophilic polymer 
chains typically have high CMCs (e.g., shown by hydrophilic polyvinylpyrrolidone (PVP)-
hydrophobic alkyl chain micelles[35]). It appears that DSPE-PCB 5K has a the balanced PCB 
MW and achieves the lowest possible CMC (< 10-6 mM (undetectable)) compared with DSPE-
PCB 2K (CMC = 1.2 - 6 x 10-5 mM) and 10K (CMC = 0.9 - 1.8 x 10-5 mM), and other reported 
micelles containing zwitterionic polymer blocks.[50] 
One major challenge with drug delivery is the dissociation of carrier entities (e.g., micelles) 
as they are infused into the blood stream since the drug carrier is typically diluted below its CMC. 
Blood serum comprises a large number of proteins (albumin) that decompose micelles and bind 
with this surfactants.[51] Compared with water, dilution in serum is even more challenging for 
assembled carrier systems. Here the stability of ultra-low CMC and conventional micelles in 
fetal bovine serum (FBS) using the gold NP probes at 0.055 mM micelle concentration was 
tested. (Fig. 2-11). It was found that DSPE-PCB 5K (ultra-low CMC) showed excellent stability 
over 72 h. Conventional Polysorbate 80 and DSPE-PEG 5K micelles were not stable; for DSPE-
PEG 5K, it dissociated at this concentration even above its CMC. The diluted micelle 
concentration tested (10-2 mM) is chosen by considering the situation of a 60 kg adult patient 
having 4.5 L blood receiving 75 mg/m2 TAXOTERE® to treat breast cancer.[52] The hypothetical 
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maximum micelle concentration (i.e. Polysorbate 80) in the blood is calculated to be 5.5 x 10-2 
mM, assuming all drug was injected simultaneously. The reality is TAXOTERE® has to be 
mixed with infusion saline and be slowly infused (typically complete in one hour).[53] As drugs 
gradually enter the blood, they are immediately diluted, with micelle concentration lower than 
10-2 mM. The serum stability test at 10-2 mM indicates that ultra-low-CMC micelles are more 
stable than conventional ones as drug carriers at clinic-relevant concentrations.  
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Figure 2-1 Ultra-low-CMC micelles and their unusual ability to stabilize cargoes in extremely 
diluted conditions with micelle concentrations far below CMCs of common micelles. Conventional 
micelles dissociate at a concentration below CMC, and thus cannot stabilize hydrophobic cargo. Structure 
for ultra-low-CMC micelles is shown. For conventional micelles, polar groups are either non-ionic (e.g., 
polysorbate 80, having hydrophobic nature) or only contained one ionic group (e.g., sodium dodecyl 
sulfate). Sharp-contrast micelles with multiple polar zwitterionic (polyzwitterionic) groups were recently 
reported[32]. 
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Figure 2-2 TEM and DLS data of DSPE-PCB 5K micelle. a, Representative TEM image for DSPE-
PCB 5K micelle (5 mM) in water taken by JEOL 2010 Transmission electron microscopy. Stained with 2% 
uranyl acetate. The scale bar in the figure is 50 nm. b, DLS data for DSPE-PCB 5K in PBS (0.5 mM), 
showing an average diameter of 20 ± 3.5 nm (mean ± SD, N = 3) with a polydispersity index of 0.13. 
 
 
a)                                                                                           b) 
 
 
 
 
 
Figure 2-3. The hydrophobic core domains of DSPE-PCB 5K micelles were detected using pyrene as 
reflected by the decrease in the intensity ratio of the first to the third highest energy bands (I1/I3) in the 
emission spectra of pyrene from 1.7 in water (a) to 1.16 in 0.17 mg/mL micelle in water (b). The 
excitation wavelength was 334 nm.  
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Figure 2-4. The CMC of DSPE-PCB 5K was determined to be 1.3 x 10-3 mM using the pyrene probe 
method (mean ± SD, N=3). 
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Figure 2-5 | “Diluting-concentrating” method to probe CMCs for micelles. Aggregation of gold probe 
at different micelle concentrations was reflected by a, hydrodynamic size of the colloid and b, gold 
maximum absorbance wavelength (mean ± SD, N=3). Dashed arrows in both figures indicate the CMC 
values. CMC data for DSPE-PEG are from reference.[35, 44] CMC data for commercial available micelles 
are provided by the manufacturers. 
 
 
a) Polysorbate 80. Non-ionic surfactant. CMC (provided by manufacture) = 0.012 mM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
b) DSPE-PEG 5K. Non-ionic surfactant. CMC (from ref[44a].) = 1-1.5 x10-3 mM 
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c) DSPE-PEG 2K. Non-ionic surfactant. CMC (from ref.[44a]) = 0.5-1 x10-3 mM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
d) CTAB. Cationic surfactant. CMC (provided by manufacturer) = 0.92 mM                                                        
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e) SDS. Anionic surfactant. CMC (provided by manufacturer) = 8.2 mM 
 
 
 
 
 
 
 
 
 
 
 
 
f) CB12C. A zwitterionic surfactant with single carboxy betaine as a hydrophilic group and 
12 carbon chain as a hydrophobic group. CMC (provided by manufacturer) = 1.5 mM 
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g) CB14C. A zwitterionic surfactant with single carboxy betaine as a hydrophilic group and 
14 carbon chain as a hydrophobic group. CMC (provided by manufacturer) = 0.034 mM 
 
 
 
 
 
 
 
 
 
 
 
h) SB10C. A zwitterionic surfactant with single sulfobetaine as a hydrophilic group and 10 
carbon chain as a hydrophobic group. CMC (provided by manufacturer) = 24~40 mM 
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i) SB16C. A zwitterionic surfactant with single sulfobetaine as a hydrophilic group and 16 
carbon chain as a hydrophobic group. CMC (provided by manufacturer) = 0.01~0.06 mM 
 
 
 
 
 
 
 
 
 
 
 
j) DSPE-PCB 5K. A zwitterionic surfactant with poly carboxy betaine as a hydrophilic group 
and DSPE chain as a hydrophobic group. CMC is undetectable < 2.7 x 10-6 mM 
    
 
 
 
 
 
 
 
 
 
 
Figure 2-6. “Diluting-concentrating” method to determine micelle CMCs using gold NPs as a probe. 
Measuring curves for all samples tested are shown (a-j), including non-ionic, cationic, anionic, and 
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zwitterionic surfactants. Aggregation of the gold probe at different micelle concentrations was reflected 
by the hydrodynamic size of the colloid and gold maximum absorbance wavelength (mean ± SD, N=3). 
Known CMC values for micelles were listed and indicated by dashed arrows. The current “diluting-
concentrating” method is able to detect a CMC as low as 2.7 x 10-6 mM.  
 
 
a) 
 
b) 
 
Figure 2-7. CaCO3 probes were encapsulated in DSPE-PCB 5K micelle, by dissolving micelles and 
CaCl2 in 10 ml deionized water followed by dropwise addition of 1 mL Na2CO3 aqueous solution under 
vigorous stirring at room temperature for 15 min (micelle:CaCl2:Na2CO3 (molar ratio) = 1:1:1). (a) The 
size of DSPE-PCB 5K/CaCO3 nanoparticles before dilution. Micelle concentration was 3 mg/mL (0.5 
mM), and CaCO3 concentration was 0.05 mg/mL (0.5 mM). (b) The size of DSPE-PCB 5K/CaCO3 
nanoparticles after 1000-fold dilution to micelle concentration of 5 x 10-7 M, and CaCO3 concentration of 
0.05 mg/L, and then concentrated back to the original concentration at (a). The solubility of CaCO3 in 
water is 0.013 mg/mL or 13 mg/L. The concentration of CaCO3 encapsulated in micelle before dilution 
26 
 
 
 
(0.05 mg/mL) was above its solubility (0.013 mg/mL), and the concentration of CaCO3 encapsulated in 
micelle after dilution (0.05 mg/L) was below its solubility (13 mg/L). CaCO3 was found to be released at 
diluted concentration and aggregated into large particles after condensation as shown at (b).  
 
 
 
 
Figure 2-8. TEM figures of DSPE-PCB 5K micelle at an extremely low concentration (2.7 × 10-6 mM). 
Stained with 2% uranyl acetate. The scale bar in the figure is 20 nm. 
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Figure 2-9 Effect of supplying zwitterionic moieties on the CMCs of conventional micelles, and 
impact of the zwitterionic PCB MW on the CMC of DSPE-PCB. a,b, Gold NPs were loaded in SDS 
(a) and Polysorbate 80 (b), and upon water dilution, their aggregation behavior (due to micelle 
dissociation) was measured by the increase in maximum absorbance peak of gold (mean ± SD, N=3). 
When 500 mg/ml CB was used as dilution solvent, no significant gold aggregation was observed in the 
dilution range, indicating a stabilized micelle (despite a concentration below its inherent CMC). In 
contrast, when 500 mg/mL OEG was used as dilution solvent, there was gold NP aggregation at high 
micelle concentrations, showing an increase of micelle CMC. CB and OEG alone (without the aid of 
micelles) cannot stabilize gold NPs, leading to aggregation. It should be noted that DLS data are not 
reliable in this experiment since the large concentration of small-sized CB or OEG moieties interferes 
with the hydrodynamic size readings for aggregated gold NPs. c, d, “Diluting-concentrating” method to 
probe CMCs for DSPE-PCB 2K, 5K, 10K micelles. Aggregation of the gold probe at different micelle 
concentrations was reflected by the gold maximum absorbance wavelength (c) (mean ± SD, N=3) and the 
hydrodynamic size of the colloid (d) (mean ± SD, N=3). CMC values were determined for DSPE-PCB 
2K and 10K and are indicated by dashed arrows. 
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e)                                                                                          f) 
 
 
 
 
 
 
 
 
 
Figure 2-10. Gold NPs were loaded in SDS (a) and Polysorbate 80 (b), and upon water dilution, 
their aggregation behavior (due to micelle disassociation) was measured by the increase in 
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maximum absorbance peak of gold (mean ± SD, N=3). When 100 mg/mL PCB polymer (MW= 
5K) was used as dilution solvent, no gold nanoparticle aggregation was observed in the dilution 
range, indicating micelles were stabilized even at a concentration below its inherent CMC. In 
contrast, when 100 mg/mL PEG polymer (MW= 5K) was used as dilution solvent, there was 
gold NP aggregation at the concentrations above the inherent CMC of micelles. PCB and PEG 
alone (without the aid of micelles) cannot stabilize gold NPs, leading to severe aggregation. It 
should be noted that DLS data are not reliable in this experiment since the presence of a large 
concentration of small size PCB or PEG interferes with the hydrodynamic size reading for the 
aggregated gold NPs. Different concentration of PCB solutions was used as dilution solvent, and 
within the concentration series, 40 mg/mL PCB was the minimum required to stabilize (c) SDS 
and (d) Polysorbate 80 upon dilution (mean ± SD, N=3). Different concentrations of CB 
solutions were used as dilution solvents, and within the concentration series, 200 mg/mL CB was 
the minimum required to stabilize (e) SDS and (f) Polysorbate 80 upon dilution (mean ± SD, 
N=3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-11 Stability of ultra-low-CMC micelle and conventional micelles with gold NP probes 
encapsulated at 5.5 × 10-2 mM micelle concentration in 100% fetal bovine serum (FBS) over 72 h at room 
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temperature. Potential micelle disassociation resulted in gold NP aggregation, which was measured by 
gold maximum absorbance peak (mean ± SD, N=3). Known CMC values for each micelle are indicated 
inside the graph.  
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CHAPTER 3 THERAPEUTIC PERFORMANCE OF DRUG/DSPE-PCB 5K 
FORMULATION   
Commercially available micelle drug formulations, such as Taxotere®, usually have 
stability issue and prematurely release drug when infused into the blood stream due to the high 
CMC values of the micelles being used. The previous Chapter described a novel zwitterionic 
micelle DSPE-PCB 5K with ultra-low CMC feature and demonstrated its stability in FBS over 
72 hours at a clinically relevant condition. Therefore, it is of interest to evaluate the therapeutic 
performance of such ultra-low CMC micelles as drug delivery carriers. In this chapter, a 
docetaxel/DSPE-PCB 5K formulation was prepared via thin film hydration method using the 
ultralow CMC micelle introduced in chapter 2. This new formulation was expected to show 
better performance due to the high stability of ultralow CMC zwitterionic micelle. To evaluate 
the anti-tumor performance of such new formulation, a melanoma tumor model on mice was 
developed. Ultralow CMC micelles encapsulating docetaxel showed full elimination of tumors, 
whereas conventional docetaxel micellar formulations did not reverse tumor growth. Ultralow 
CMC micelles might become next-generation carriers for drug delivery. 
3.1 Introduction 
A well-known micelle based drug formulation is Taxotere®, a chemotherapy medication 
used to treat a number of types of cancers. One single-dose vial of Taxotere® contains the active 
ingredient docetaxl, polysorbate 80 micelle molecule and anhydrous ethanol. Clinically, this 
formulation required dilution in 250 mL infusion bag containing 0.9% sodium chloride or 5% 
dextrose and was then slowly infused into the blood stream which lasted for 1 hour. There are 
two limitations for this formulation: 1) Fully prepared Taxotere infusion solution, the diluted 
form, should be used within 4 hours including the 1 hour i.v. adinistration due to the low stability 
of the micelle formualtion. 2) When infusing into the blood, the concentration of polysorbate 80 
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(<< 5.5 × 10-2 mM) is much lower than its CMC value (0.012 mM). At such low concentration, 
polysorbate 80 would disassemble into free surfactants and cannot stabilize and carry docetaxel 
for blood circulation. In Chpater 2, zwitterionic micelle DSPE-PCB 5K was demonstrated to 
have an ultralow CMC value and showed high stability in clinical-relavant environment. 
Therefore, a new docetaxel formulation was prepared using zwitterionic micelle, and its 
therapeutic outcome was examined by intravenously injecting to mice inoculated with melanoma 
tumor (B16F10). Melanoma is a challenging disease to treat due to the well-documented chemo-
resistance[54]. Docetaxel was not clinically used to treat melanoma, but had been explored to treat 
melanoma in animal studies through nanoparticle mediated delivery, though with marginal 
improvement of the therapeutic outcome[55]. Considering the advantage of the ultralow CMC 
zwitterionic micelle, it is curious to know if the new micelle formulation of the old drug can 
enhance therapeutic treatment of melanoma in animal studies.    
3.2 Materials and Methods 
3.2.1 Materials 
Docetaxel was obtained from LC Laboratories (Woburn, USA). B16F10 cells were 
obtained from ATCC. Trifluoroethanol, Phosphate-Buffered Saline tablets, and acetonitrile (LC 
grade) were purchased from Sigma-Aldrich (St. Louis, USA). RPMI 1640 medium was 
purchased from Gibco (Dublin, Ireland). 
 
3.2.2 Preparation of docetaxel/DSPE-PCB 5K formulation 
To prepare docetaxel/DSPE-PCB 5K formulation, 150 mg of DSPE-PCB 5K and 6 mg 
docetaxel were co-dissolved in 5 mL trifluoroethanol in a round-bottom flask. The solvent was 
evaporated by rotary evaporation to obtain a thin film. The film was kept in a vacuum for 2 hours 
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at room temperature to remove the residual trifluoroethanol. After the addition of 3 mL saline 
and stirring at 800 rpm for 30 min, a transparent micelle solution with docetaxel loaded was 
obtained. Docetaxel/DSPE-PEG 5K and docetaxel/Polysorbate 80 formulations were prepared 
following the same procedure. Taxotere was prepared following a reference procedure[52-53, 56]. 
The weight ratios of the drug over surfactant for all formulations were kept at 4%, which is the 
drug loading level for TAXOTERE®[57]. 
Drug release profiles were determined by placing 100 μL different formulations into Slide-
A-Lyzer MINI dialysis microtubes (3500 Da MW cutoff) and dialyzed against PBS at 37 oC with 
gentle stirring. At different time intervals, docetaxel remained in the dialyzer was quantified 
through HPLC by a Waters Breeze 2 System equipped with a Waters 2998 photodiode array 
detector at 230 nm and a Waters Symmetry C18 column (4.6 × 7.5 mm). The mobile phase was a 
mixture of acetonitrile/water (50:50 volume/volume) at a flow rate of 1 mL/min. The docetaxel 
showed a single elution peak at 5.47 min.    
 
3.2.3 Animal Experiments 
The animal experiment was approved by the Institutional Animal Care and Use Committee 
(IACUC) of Wayne State University, and performed in compliance with relevant laws and 
institutional guidelines. B16F10 cells (ATCC, CRL-6475) were cultured in RPMI 1640 medium 
containing 10% fetal bovine serum at 37 oC under a 5% CO2 atmosphere. For in vivo tumor 
therapeutic studies, healthy C57BL/6 mice (7 weeks old, 20-25 g) received a subcutaneous 
injection of 100 μL B16F10 cells (5 × 106 cells/mL) in the right flank. After 8 days of inoculation, 
the tumor became visible, and different formulations were administered by intravenous injection 
via tail vein 5 times every other day at the dosage of 10 mg docetaxel/kg body weight. The tumor 
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volume of the mice was measured day by day and calculated with an equation of (L×W2)/2 
where L is the long length, and W is the short length of the tumor. Mice were euthanized if their 
weight loss exceeded 15% or if their tumor grew to a volume greater than 1000 mm3. For 
maximum tolerated dose (MTD) study, healthy C57BL/6 mice received one intravenous 
injection of different docetaxel formulations through the tail vein at the dose of 25 mg/kg, 40 
mg/kg, or 55 mg/kg. Treated mice were subsequently observed day by day and checked for 
mortality, body weight, and signs of toxicity. To measure docetaxel concentration in plasma, 
healthy C57BL/6 mice (7 weeks old, 20-25g) were treated with intravenous injection via tail vein 
at the dosage of 10 mg/kg. At different time intervals, 50 µL blood samples were collected and 
transferred to sodium heparin treated tubes. Docetaxel was extracted from the plasma 
supernatant with ethyl acetate, and the extracted solution was evaporated under a gentle stream 
of nitrogen. The extraction residues were reconstituted in the mixture of acetonitrile/water (50:50 
volume/volume). The docetaxel concentration was measured using HPLC as mentioned above. 
To test bio-distribution, healthy C57BL/6 mice (7 weeks old, 20-25 g) received a 
subcutaneous injection of 100 µL B16F10 cells (5 × 106 cells/mL) in the right flank. After 8 days 
of inoculation when tumors became visible, different formulations were administered by 
intravenous injection via the tail vein. Mice were euthanized at the certain time point. Organs 
(liver, heart, kidney, spleen, lung and tumor tissues) were collected, thoroughly washed with 
saline (0.9% NaCl), weighted, and stored for further analysis. Organs or tissues were 
homogenized with Mini-beadbeater-24 (Biospec Products, Inc., USA) in acetonitrile/water 
(50:50 volume/volume). The resulting 200 µL samples of homogenized tissue were mixed with 1 
mL ethyl acetate. Well-mixed samples were then centrifuged at 4000 g for 5 minutes. The 
organic layer was transferred to a clean tube and evaporated under a gentle stream of nitrogen. 
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The extraction residue was reconstituted in 1 mL mixture of acetonitrile/water (50:50 
volume/volume).  The docetaxel concentration was measured using HPLC. 
3.3 Results and Discussion 
To study the applicability of using ultra-low CMC micelles to deliver real drugs, anti-
tumor drug docetaxel was chosen and docetaxel/ DSPE-PCB 5K formulation was prepared using 
a simple thin-film hydration method (see Experimental Section)[57-58]. Control formulations 
include docetaxel/Polysorbate 80 and docetaxel/DSPE-PEG 5K, similarly made through thin-
film hydration method, and Taxotere® formulated based on literature reports[52-53, 56]. The weight 
ratios of the drug over surfactant for all formulations were kept at 4%, which is the drug loading 
level for Taxotere®[57]. The hydrodynamic diameters for all tested samples were around 22 nm 
as determined by DLS. However, after diluting these samples in FBS to reach micelle 
concentration of 5.5 × 10-2 mM (the hypothetical maximum micelle concentration in the blood), 
only docetaxel/ DSPE-PCB 5K can maintain its hydrodynamic size, while all other control 
formulations appeared to be unstable over the tested time period (Fig. 3-1). Drug release profiles 
were determined by placing the formulations into Slide-A-Lyzer MINI dialysis microtubes 
(3500Da MW cutoff) and dialyzed against PBS at 37 oC with gentle stirring. Docetaxel remained 
inside the dialysis tubes at different time points was quantified using HPLC to calculate drug 
release. DSPE-PCB 5K showed the highest retention of docetaxel compared with other control 
micelles, with 50% drug released in 3.7 h (Fig. 3-2). The drug release mechanism in 
docetaxel/DSPE-PCB 5K formulation is expected to be based on drug dissolution or drug 
leaching. This has been indicated by the control study showing the zwitterionic micelles can 
stabilize non-dissolvable gold NPs and crosslinked PS NPs but not soluble CaCO3 NPs at low 
concentrations (5 × 10-4 mM). The stability of different docetaxel formulations after 
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lyophilization was further checked. Results indicated that after lyophilization docetaxel/DSPE-
PCB 5K maintained its original hydrodynamic size, while all control micelle formulations 
aggregated (Fig. 3-3).   
The maximum tolerated dose (MTD) of docetaxel/ DSPE-PCB 5K was determined using 
healthy C57BL/6 mice to be 55 mg docetaxel/kg body weight, significantly higher than control 
formulations docetaxel/DSPE-PEG 5K (40 mg/kg), docetaxel/Polysorbate 80 (40 mg/kg), and 
Taxotere® (25 mg/kg) (Fig. 3-4). To examine the antitumor activity of different 
docetaxel/micelle formulations, C57BL/6 mice were inoculated with B16F10 cells in the right 
flank. On day 8 after inoculation, they received an intravenous injection of one of the drug 
formulations, followed by 4 more every other day. The dose for all drug/micelle formulations 
was 10 mg docetaxel/ kg body weight. Docetaxel/DSPE-PCB 5K showed significantly better 
anti-tumor activity compared with all other micellar docetaxel formulations, including 
Taxotere® (Fig. 3-5a). All tumors treated with this formulation were eliminated by day 33 after 
the first treatment, without recurrence over the 70 days observation period after tumor 
inoculation (Fig. 3-5b and Fig. 3-5c). None of the control formulations based on docetaxel were 
able to fully inhibit the melanoma tumor. In fact, it is rare for any chemotherapy drugs to 
completely eliminate melanoma[31c, 59].  
To further investigate the in vivo circulation profile of docetaxel/DSPE-PCB 5K, different 
docetaxel formulations were injected intravenously to healthy C57/BL6 mice. At different time 
points, blood samples were collected, and the concentration of docetaxel in plasma was 
measured via HPLC. It was found that docetaxel/DSPE-PCB 5K showed longer blood 
circulation than all other micellar docetaxel formulations (Fig. 3-6). The α and β half-life of 
docetaxel/DSPE-PCB 5K were calculated to be 0.6 hours and 5.9 hours, while for 
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TAXOTERE® these values were 4 min and 36 min, respectively. For bio-distribution, healthy 
C57/BL6 mice were treated with intravenous injection of different docetaxel formulations after 
inoculation of B16F10 cells. Bio-distribution of docetaxel at different time points has been 
further studied. Significantly higher tumor accumulation of docetaxel/DSPE-PCB 5K was 
observed at 24 hours post-injection compared with control formulations (Fig. 3-7). Such 
enhanced drug accumulation to tumor site has been observed at as early as 2 hours after 
administration (Fig. 3-8).  The antitumor performance of docetaxel/DSPE-PCB 5K formulation 
was attributed to the stabilization ability of the ultra-low CMC micelle which improved the blood 
circulation and drug accumulation in tumor.  
In summary, the ultra-low CMC zwitterionic micelle was used to prepare a new 
formulation of docetaxel. Therapeutic performance was evaluated on a melanoma model and 
compared with Taxotere and other controls. Results showed that the docetaxel/ ultra-low CMC 
micelle formulation can completely eliminate the melanoma tumor on mice, while the control 
formulations, including TAXOTERE®, was unable to do so. Excellent therapeutic performance 
was attributed to the ultra-stability in protecting cargoes without dissociation. Therefore, it is 
expected the ultra-low CMC micelle can be utilized to enhance the delivery and therapeutic 
effects of other drugs in general. 
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Figure 3-1. Stability of different docetaxel formulations diluted in FBS (mean ± SD, N=3). 
 
 
 
 
 
 
 
 
 
Figure 3-2. The release profile of different docetaxel formulations in dialysis against PBS. (mean ± SD, 
N=3) 
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Figure 3-3. Stability of different docetaxel formulations as reflected by the hydrodynamic size of the 
formulation before and after lyophilization (mean ± SD, N = 3). The circles in each bar represent an 
original data point.  
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Figure 3-4.  Dose escalation in healthy mice. Solutions of different formulations a, Taxotere; b, 
docetaxel/DSPE-PCB; c, docetaxel/DSPE-PEG; d, docetaxel/Polysorbate 80 were administered through 
intravenous tail vein injection. (mean ± SD, N=3). 
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(a) 
 
 
 
 
 
 
 
 
(b)                                                                           (c) 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-5. (a)Anti-tumor performance of docetaxel/DSPE-PCB 5K formulation (mean ± SD, N = 7) 
compared with other formulations (mean ± SD, N = 7). On day 10 after treatment (*), a Mann-Whitney 
Test indicated that docetaxel/DSPE-PCB 5K delayed the tumor growth greater than all other four controls 
at p = 0.005. (b), Survival rate curves of mice treated with the different formulations. (c), Probability of 
cure. In mice bearing invisible tumors < 1mm3 in size or a flattened and darkened scar tissue developed, it 
was considered that the tumor had been completely eradicated. Lines representing docetaxel/DSPE-PEG 
5K, docetaxel/polysorbate 80, taxotere and PBS are overlapped.  
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Figure 3-6. The concentration of docetaxel in blood plasma of different formulations (mean ± SD, N = 4). 
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Figure 3-7. Bio-distribution of different docetaxel formulations at 24 hours post i.v. injection (mean ± SD, 
N= 4). One-Way ANOVA analysis with Bonferroni multi-comparison: significant difference between 
docetaxel/DSPE-PCB 5K and docetaxel/DSPE-PEG 5K, docetaxel/DSPE-PCB 5K and 
docetaxel/Polysorbate 80, docetaxel/DSPE-PCB 5K and Taxotere, at p < 0.001 (***), p < 0.0001 (****), 
and p < 0.0001 (****), respectively.  
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Figure 3-8. Bio-distribution of different docetaxel formulations. a, bio-distribution of docetaxel from 
different formulations at 2 hours post i.v. injection (mean ± SD, N= 4). One-Way ANOVA analysis with 
Bonferroni multi-comparison: significant difference between docetaxel/DSPE-PCB 5K and 
docetaxel/Polysorbate 80, docetaxel/DSPE-PCB 5K and Taxotere, at p < 0.01 and p < 0.05, respectively. 
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No significant difference between docetaxel/DSPE-PCB 5K and docetaxel/DSPE-PEG 5K. b, bio-
distribution of docetaxel from different formulations at 8 hours post i.v. injection (mean ± SD, N= 4). 
One-Way ANOVA analysis with Bonferroni multi-comparison: significant difference between 
docetaxel/DSPE-PCB 5K and docetaxel/DSPE-PEG 5K, docetaxel/DSPE-PCB 5K and 
docetaxel/Polysorbate 80, docetaxel/DSPE-PCB 5K and Taxotere, at p < 0.01, p < 0.0001, and p < 0.001, 
respectively.  
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CHAPTER 4. SIMPLE PROTEIN MODIFICATION USING 
ZWITTERIONIC POLYMER  
 In this chapter, it is demonstrated that when the zwitterionic carboxybetaine polymer 
(PCB) was conjugated to insulin through simple conventional coupling chemistry, the resulting 
PCB-insulin did not show a significant reduction of in vitro bioactivity. The reported simple 
strategy of using PCB for protein conjugation is expected to solve the bioactivity loss issue for 
most protein-polymer conjugations. The obtained PCB-insulin shows two significant advantages 
as a novel pharmaceutical agent. First, for PCB-insulin, in vivo pharmacological activity of 
lowering blood glucose was increased compared with native insulin. Such increase is expected to 
be due to both the improved pharmacokinetics and retained bioactivity of PCB-insulin. Second, 
its production is simple from manufacturing standpoints. The conjugation procedure involves 
only one-step coupling reaction and does not require a site-specific linkage technique. The 
synthesized PCB-insulin conjugates do not need chromatographic separation to purify. These 
two advantages are expected to be translated to other types of therapeutic proteins as well. 
 
4.1 Introduction 
The major purpose of polymer-protein conjugation is to improve pharmacokinetics 
(PK) and retain bioactivity in order to improve the pharmacological activity (the inherent 
capacity of drug to alter chemical or physiological functions of a cell, tissue organ or 
organism) of a modified protein.[60] The most widely used conjugation strategy is 
PEGylation that uses polyethylene glycol (PEG) to conjugate proteins.[25] Despite 
improved PK, PEGylation is known for its sacrificing the conjugated protein activity.[26] 
Results indicate that conjugating PEG, and other commonly seen polymers as well, on 
proteins through conventional covalent coupling chemistry resulting in polymer chains 
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non-selectively attached on the protein surface groups (e.g., amines), and potential 
attachment near a protein’s active site inhibit the protein from performing designated 
biological function (e.g., amine group on Gly A1 of insulin)[27]. There are alternative 
methods allowing for site-specific conjugation to proteins, e.g., involving re-engineering 
the proteins, or laborsome separation, but those procedures are complex.[61] When PEG is 
conjugated to proteins in a site-selective manner, however, the resulting PEG-proteins are 
still subject to bioactivity loss. Eli Lily has developed a PEGylated insulin Lispro 
(LY2605541) where a 20 kDa PEG was conjugated at the amino group of Lys B28 of 
insulin Lispro. For LY2605541, a high molar concentration is still required to achieve 
comparable glucose lowering effect to the unconjugated insulin as observed in the in vitro 
insulin receptor binding studies.[62]  
In this chapter, it is reported that the conjugation of zwitterionic carboxybetaine 
polymer (PCB) on insulin through conventional coupling chemistry improves the PK of 
the protein, but does not compromise the insulin in vitro bioactivity. Remarkably, this 
conjugation strategy increases the in vivo glucose lowering activity for ~24% compared 
with native insulin at equal molar dose when intravenously (i.v.) injected. In addition, the 
synthesis of PCB-insulin does not require complicated site-specific linkage technique and 
can be implemented through a simple one-step coupling reaction. The resulting PCB-
insulin conjugates do not require chromatographic separations to obtain purified isoforms, 
potentially enabling a simplified scaling-up, and manufacturing procedure. 
 
4.2 Materials and Methods 
4.2.1 Materials 
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Human recombinant insulin was purchased from Life Technologies Corporation. 
Methoxypolyethylene glycol 5000 Da acetic acid N-succinimidyl ester (PEG-NHS), 
streptozotocin (STZ), Cu(I)Br, and all necessary solvents were purchased from Sigma-Aldrich. 
HEPES buffer was purchased from Hyclone.  
4.2.2 Synthesis of PCB-(N-hydroxysuccinimide) (NHS) 
PCB-NHS was synthesized based on a previous procedure.[32] Briefly, NHS-PCB-tBu was 
firstly synthesized through atom transfer radical polymerization (ATRP) of 2-tert-Butoxy-(2-
(methacryloyloxy)ethyl)-dimethyl-2-oxoethanaminium (CB-tBu), which was carried out in 
anhydrous dimethylformamide (DMF), initiated by N-hydroxysuccinimide 2-bromopropanoate 
and catalyzed by Cu(I)Br/1,1,4,7,10,10-hexamethyltriethylenetetramine (HMTETA). The 
resulting NHS-PCB-tBu was purified through precipitation in acetone, and later treated with 
trifluoroacetic acid to obtain PCB-NHS, which was further precipitated in ethyl ether, and dried 
under vacuum condition.  
4.2.3 Synthesis of PCB-insulin and PEG-insulin 
Conjugates of PCB-insulin and PEG-insulin were synthesized by reacting NHS ester 
groups of the polymer with available amine groups on the protein. Typically, insulin (1 mg/mL) 
was dissolved in 0.1 M Na2CO3 buffer. The insulin stock solution was homogeneously divided 
into three portions, with one as free insulin sample, and the other two for conjugation with PCB 
and PEG, respectively. For the conjugation reaction, pre-dissolved PCB-NHS 5K or PEG-NHS 
5K was added into the insulin solution at polymer: insulin molar ratio = 1.2:1, and the reaction 
mixture was stirred at 700 round/min rate at 0 °C, for one hour to obtain the PCB-insulin or 
PEG-insulin rough products. After the reaction, the buffer was adjusted to pH 7.4 by HCl. To 
obtain PEG-insulin and PCB-insulin where most of the three amines of insulin were conjugated 
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with PEG or PCB, pre-dissolved PCB-NHS 5K or PEG-NHS 5K was added into the insulin 
solution at polymer: insulin molar ratio = 20:1 in 0.2 M HEPES buffer, and the reaction mixture 
was stirred at 400 round/min rate for 40 hours. 
  
4.2.4 Purification of PCB-insulin and PEG-insulin 
To purify PCB-insulin and PEG-insulin, the rough conjugation products were placed in a 
dialysis kit (6-8 kDa MWCO, Sigma-Aldrich). The MW cut off retains the polymer-insulin 
conjugates, but allows both free insulin and unconjugated PCB-NHS or PEG-NHS to go through 
the membrane. Completion of purification was indicated by observing no unconjugated insulin 
or polymer partitioned to the solvent phase outside of the dialysis tubing. Unconjugated insulin 
can be detected using UV-vis spectrometer (at 276 nm). Also, both unconjugated insulin and 
polymer can be sensitively detected by DLS (Zetasizer Nano-ZS, Malvern); a dialysate solution 
with the count rate (the number of photons detected per second) as low as that of pure water 
indicating that the solution is free of insulin or polymer. The purified polymer-insulin samples 
were desalted using a PD-10 column and freeze-dried for storage. To quantify the molar 
concentration of purified PCB-insulin and PEG-insulin solution sample, both methods of UV-vis 
absorbance (276 nm) and a Mercodia human insulin ELISA assay were used. 
4.2.5 Other Characterization 
The hydrodynamic sizes of the insulin and its conjugate samples were measured by a DLS 
method using a Malvern Nano-ZS Zetasizer at 25 oC. The samples of free insulin, PEG-insulin 
and PCB-insulin were dissolved in 0.2M HEPES buffer and analyzed on an Autoflex III matrix-
assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS, Bruker 
50 
 
 
 
Daltonics). The mass spectra were collected with a repetition rate of 100 Hz, accelerating voltage 
of 19 kV and an average of 700 shots. The data were analyzed with Biotools program (Bruker).  
CD spectra were collected by using a Chirascan spectrophotometer from Applied 
Photophysics at 25 oC. Insulin samples were dissolved in PBS buffer at 0.2 mg/mL. The CD 
spectra were measured from 200 to 250 nm with the light-path length of 1 mm. The scanning 
speed of CD spectra measurement was set at 200 nm/min. Each spectrum was the average of 
three scans to increase the signal-to-noise ratio of the measurements. The secondary structure 
proportions for insulin and its conjugates were analyzed using CDSSTR software.  
For insulin bioactivity test, about 25,000 CHO-M1 cells/well (ATCC) were seeded in a 96-
well tissue culture treated plate and incubate for 24 h before being cultured in serum-free 
medium. These cells were then treated with 10 μg/mL native insulin, PEG-insulin, and PCB-
insulin samples, respectively, for 45 minutes. Then cells were lysed, and a commercially 
available kit (Cisbio) was used to assay phosphorylated AKT at Ser473. The fluorescence 
emission at 665 and 620 nm was measured on an HTRF reader (BioTek, USA).   
 
4.2.6 Animal Experiments 
All animal experiments were performed according to the National Institute of Health (NIH) 
guidelines for animal research under a protocol approved by the Institutional Animal Care and 
Use Committee (IACUC) at Wayne State University. To establish streptozotocin (STZ)-induced 
diabetic mice model, healthy mice (C57BL/6J, male, 6-8 weeks of age, Jackson Lab) received a 
daily i.p. injection of 5 mg/mL STZ at 50 mg/kg for 5 consecutive days. 17 days after the first 
injection, body weight and blood glucose were measured to confirm the diabetic status. Only 
mice whose nonfasted blood glucose levels are above 300 mg/dL for two consecutive days were 
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considered diabetic for further in vivo testing. To examine the blood glucose lowering effect of 
insulin after conjugation, diabetic mice received 10 nmol/kg body weight of free insulin, crude 
products and purified forms of PCB-insulin and PEG-insulin through tail vein injection (mouse 
group size = 6). 5-10 µL blood samples were collected from the tail for glucose testing using a 
clarity plus blood-glucose meter at predetermined time intervals. The mice fasted during the 
glucose testing period. To examine blood circulation profile of insulin after conjugation, diabetic 
mice received 10 nmol/kg body weight of free insulin, purified PCB-insulin and purified PEG-
insulin through the tail vein (mouse group size = 6). At predetermined time intervals, 25 µL 
blood samples were collected from the tail vein. The insulin concentration in the blood serum 
was determined using a Mercodia human insulin ELISA assay. The mice fasted during the blood 
insulin testing period. 
 
4.3 Results and Discussion 
Zwitterionic polymer materials have attracted increasing attention as novel non-
fouling materials.[63] Particles with surfaces modified with zwitterionic polymers, such as 
PCB, have been found to efficiently avoid interactions with plasma proteins and uptake 
by the reticuloendothelial system (RES),[63a, 64] show significantly prolonged blood 
circulation half-life (improved PK),[32, 64] and demonstrated reduced immunogenicity.[65] 
Here, the general strategy in obtaining PCB-insulin conjugate is by reacting an N-
hydroxysuccinimide (NHS) ester terminated PCB with the available amine groups of 
human recombinant insulin (Figure 4-1a). To prepare PCB-insulin conjugate, NHS ester 
terminated PCB (PCB-NHS) was synthesized following established procedures.[32] The 
MW for PCB-NHS is ~5000 Da as previously reported: Mn = 4890 Da determined by 1H 
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NMR, Mn= 5410 Da, polydispersity = 1.03 characterized by gel permeation 
chromatography (GPC).[32] Then PCB-NHS was reacted with the amine group of insulin 
at PCB-NHS: insulin molar ratio of 1.2:1 to synthesize PCB-insulin conjugate. The 
reaction was conducted in a Na2CO3 solution (pH > 10) at which condition the acylation 
may occur at any of the three amines (GlyA1, PheB1, or LysB29), but is prioritized at 
epsilon amine of LysB29.[66] The LysB29 epsilon amine is the most basic with a pKa of 
approximately 10. Hence at pH = 10, LysB29 is preferred for most nucleophilic agents.  
In a similar way, PEG-insulin control was obtained by reacting a commercially available 
PEG-NHS (5000 Da, MW) with insulin. A purification method was developed using a 6-8 
kDa MWCO dialysis kit to remove unreacted insulin (~5800 Da) and unconjugated PCB-
NHS or PEG-NHS (about 5000 Da). The purified PCB-insulin and PEG-insulin were 
analyzed by MALDI-TOF MS. (Figure 4-1b). The obtained PCB-insulin and PEG-
insulin were NOT further separated to obtain their respective purified isoforms (i.e., a 
polymer conjugated to LysB29 of insulin) before evaluating their PK and bioactivity. 
The obtained PCB-insulin was first evaluated for its improved blood circulating 
potential or PK. The hydrodynamic size of conjugated proteins is a major factor 
determining theirs in vivo blood circulation behavior.[14n, 62a, 67] An increase in 
hydrodynamic size typically supersedes the renal ultrafiltration cut-off and reduces the 
glomerular filtration of modified proteins. A prolonged blood circulation half-life has 
been extensively reported for PEGylated proteins.[68] We measured the hydrodynamic size 
of conjugated insulin with dynamic light scattering (DLS) method by using a Malvern 
Nano-ZS Zetasizer (Figure 4-2a). The hydrodynamic sizes of insulin, PEG-insulin, and 
PCB-insulin in pH 8.4 HEPES buffer are 1.4±0.2 nm, 2.8±0.7 nm, and 2.2±0.6 nm, 
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respectively (average ± standard deviation, n=3). Similar to PEG-insulin, there is a 
significant hydrodynamic size increase for PCB-insulin over native insulin, implying 
potentially protracted blood circulating lifetime for PCB-insulin. 
The PK of PCB-insulin was examined in a diabetic mouse model. All animal 
experiments were performed according to the National Institutes of Health (NIH) 
guidelines for animal research under a protocol approved by the Institutional Animal Care 
and Use Committee (IACUC) at Wayne State University. C57BL/6 mice received a daily 
i.p. injection of 5 mg/mL streptozocin (STZ) at 50 mg/kg for 5 consecutive days. STZ-
mice were placed on a nonfasted regular diet. 17 days after the first injection, weight and 
blood glucose were measured to confirm diabetic status. Only mice whose nonfasted 
blood glucose levels are above 300 mg/dL for two consecutive days were considered 
diabetic. Insulin and purified polymer-insulin conjugates were injected into three groups 
of diabetic mice through the tail vein at an equal molar dose of 10 nmol/kg. Blood 
samples were collected at various time intervals, and the concentration of serum insulin 
was quantified with human insulin ELISA assay (Figure 4-2b). The relative area under 
the curve (AUC) was calculated, and the blood circulation half-life (t1/2) was obtained to 
fit a one-compartment model[32] (Table 4-1). The AUCs for both PCB-insulin and PEG-
insulin are larger than that of native insulin. The relative AUC for PCB-insulin is almost 
1.43 times of that of native insulin. t1/2 for PCB-insulin (4.2 h) and PEG-insulin (3.6 h) are 
significantly longer than free insulin (2 h). Typically, elimination half-life indicates the 
time necessary for the amount or the concentration of drug in serum or plasma, to reduce 
by 50%. Half-life is usually regarded as the most reliable indicator of the rate of drug 
removal by the body[69]. The rate of removal is expected to be slow when the half-life is 
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long, which implies a long effective duration of the drug in the blood circulation[70]. The 
data here indicate that the modified insulin using both PCB and PEG showed prolonged 
blood circulation effect compared with naked insulin. 
The obtained PCB-insulin was secondly evaluated for potential bioactivity change. the 
effect of polymer conjugation on the secondary structure of insulin was studied, since proteins 
generally require stabilized structures to contain their particular bioactivity.[71] Circular 
Dichroism (CD) Spectroscopy has been widely involved in characterizing the secondary 
conformation of insulin and its derivatives,[68a, 72] and was used here to evaluate free insulin, 
PCB-insulin, and PEG-insulin (spectra in Figure 4-3a; quantified results of secondary structures 
in Table 2). We found that the percentage of α-helix structure for PEG-insulin is 46%, and is 
slightly less than that for free insulin which is 50%. The random coil structure proportion for 
PEG-insulin is 30% and is more than 24% for free insulin. A similar trend has been reported in 
the literature for PEG conjugated insulin,[68a] indicating a slightly destabilizing effect on the 
protein structure. For the CD spectrum of PCB-insulin (Figure 4-3a), there is an obvious 
decrease of the negative peak at 222 nm, indicating the increase of α-helix structure. Quantified 
results (Table 2) show that the α-helix structure proportion of PCB-insulin is 53% (slightly more 
than 50% of insulin), and the random coil structure proportion is 23% (a little less than 24% of 
insulin). This suggests that the conjugation of PCB has a moderate stabilizing effect on the 
secondary structure of insulin, and implies the potential retention of insulin bioactivity after PCB 
conjugation.  
In vitro activity of PCB-insulin was tested using a cell-based protein kinase B 
phosphorylation assay. Briefly, 25,000 CHO-M1 cells/well (ATCC) were seeded in a 96-
well tissue culture treated plate and incubated for 24 h before being cultured in serum-free 
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medium overnight (12 hours). These cells were then treated with 50 µL of native insulin, 
rough products of PEG-insulin and PCB-insulin without any purification (containing both 
conjugated and unconjugated insulin), or purified products of PEG-insulin and PCB-
insulin (containing solely of conjugated insulin) for 45 minutes. The effective insulin 
concentration in each of the sample was maintained at 2 nmol/mL. For rough conjugate 
products (unpurified), the effective insulin concentration can be easily controlled by the 
feeding molar content of insulin for the conjugation reaction. For purified conjugate 
products, we used both UV-vis absorbance (276 nm), and a Mercodia human insulin 
ELISA assay to quantify effective insulin concentration. Then treated cells were lysed, 
and a commercially available kit (Cisbio) was used to assay phosphorylated AKT at 
Ser473. Figure 4-3B indicates that there was no significant decrease of in vitro 
bioactivity of both the rough and purified zwitterionic PCB-insulin, but decrease on the 
PEG-insulin was observed. The purified PEG-insulin lost ~27% activity compared with 
native insulin.  
The obtained PCB-insulin was lastly evaluated for its in vivo pharmacological 
activity. STZ induced diabetic was treated with i.v. injection of PCB-insulin and their 
blood glucose concentration at various time points following the injection were 
monitored. Diabetic mice received free insulin, as well as PCB-insulin and PEG-insulin 
rough products without any purification (containing both conjugated and unconjugated 
insulin), to the mice, at the dose of 10 nmol insulin or its conjugate /Kg (for native insulin 
dose, 10 nmol/kg = 1.5 IU/kg). The in vivo pharmacological activity of insulin samples 
was evaluated by quantifying the area above the curve (AAC) of the relative intensity of 
blood glucose concentration. In Figure 4-3C, there was no significant difference of blood 
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glucose lowering abilities between PEG-insulin and native insulin (student t-test). 
However, PCB-insulin shows significantly higher blood glucose lowering ability than 
native insulin at p < 0.05 in a student t-test (Figure 4-3C). We further injected free 
insulin, as well as purified PCB-insulin and PEG-insulin samples to the mice at the dose 
of 10 nmol/Kg. The purified PEG-insulin did not show any better glucose lowering effect 
than native insulin (Figure 4-3D). But the purified PCB-insulin sample had even higher 
blood glucose lowering ability than native insulin (Figure 4-3D), and then its non-
purified form as well (by comparing Figure 4-3C and 4-3D). The pharmacological 
activity of PEG-insulin is about 97.5% which showed no significant difference comparing 
with that of native insulin (100%). For PCB-insulin, pharmacological activity is about 
124.3% which showed significance at p < 0.005 by comparing the AACs for PCB-insulin 
and free insulin in a student t-test. 
It should be noted that a typical rough product of PCB-insulin contains 
unconjugated insulin, PCB-conjugated insulin and unconjugated PCB polymer. If PCB 
polymers were proved to be non-toxic (in a future work), such rough product can 
potentially be directly used as a medicine to minimize the cost by not wasting the un-
conjugated insulin in a purification process. 
Despite many possible factors proposed, long half-life in blood circulation has been 
considered to be the most important reason responsive to the high pharmacological 
activity of proteins.[26a, 73] The increased in vivo pharmacological activity of PCB-insulin 
was attributed to its prolonged blood circulation lifetime plus the retained in vitro 
bioactivity. PEG-insulin also showed a longer blood circulation character, but because of 
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the loss of in vitro bioactivity, its overall in vivo pharmacological activity did not show 
improvement over native insulin.  
The reason for PCB conjugation to retain in vitro bioactivity of the modified insulin 
might share a similar mechanism to a previously reported PCB conjugated enzyme 
system. PCB conjugation to α-chymotrypsin did not sacrifice the protein’s catalytic 
activity, which has been attributed to the superhydrophilic nature of PCB polymer that did 
not interfere with the hydrophobic-hydrophobic, substrate-binding site interaction.[26a] By 
contrast, PEG weakened such interaction with its amphiphilic nature and imposed steric 
hindrance.[26a] Retained bioactivity of PCB-insulin can be similarly explained by the 
unimpeded insulin ligand-receptor interaction.  
It should be noted that our coupling condition was controlled to have one PCB 
polymer chain to be conjugated preferentially at LysB29 of insulin to produce PCB-
insulin of even higher in vivo pharmacological activity than native insulin. Nevertheless, 
when PCB was conjugated to three amines of insulin (Figure 4-4), there was a drastic 
loss of in vitro bioactivity (Figure 4-5A) and the in vivo pharmacological activity as well 
(Figure 4-5B), potentially due to the occupation of Gly A1 near to the insulin’s active 
site.  
To summarize, results in this project indicate that one-PCB-chain modification per 
insulin obtained from conjugation chemistry shows improved PK, retained in vitro 
bioactivity and increased in vivo pharmacological activity of lowering blood glucose 
compared with native insulin.   
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Figure 4-1. (a) The schematic illustration of PCB conjugation with native recombinant human insulin. 
There are three amino acids with free amino groups (GlyA1, PheB1, and Lys B29) that are available for 
PCB conjugation. The disulfide bonds in insulin were labeled with yellow sticks.  (b) MALDI-TOF Mass 
spectra of native insulin, PEG-insulin, and PCB-insulin. 
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Fig. 4-2 (a) Hydrodynamic sizes for insulin, PEG-insulin, and PCB-insulin, respectively, as measured by 
DLS. Samples were dissolved in 0.2 M pH8.4 HEPES buffer. (b) The serum insulin concentration as a 
function of time after the tail vein injection of free insulin, PEG-insulin, and PCB-insulin, respectively. 
The data are presented as the percentage of the initial values of serum insulin concentration over time ± 
standard deviation (n=6). 
 
 
 
Samples Relative area under 
the curve (AUC) 
Half-life 
elimination 
time (t1/2) (h) 
 Insulin 341 ± 24 2.0 ± 0.3 
PEG-insulin 447 ± 30 3.6 ± 0.3 
PCB-insulin 466 ± 34 4.2 ± 0.3 
 
Table 4-1: The relative area under the curve (AUC) and elimination half-life (t1/2) of native insulin 
and its conjugates in blood serum. Data are illustrated by average ± standard deviation, n=6. 
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Fig. 4-3. (A) Circular dichroism (CD) spectra of native insulin, PEG-insulin, and PCB-insulin (0.2 
mg/mL insulin or conjugates at 0.2 M pH8.2 PBS buffer). (B) The bioactivity of native insulin, rough 
PEG-insulin, purified PEG-insulin, rough PCB-insulin, and purified PCB-insulin, as measured by 
phosphorylation of the insulin receptor in vitro. The relative activity was presented as the percentage 
relative to native insulin ± standard deviation (n=6). *p < 0.05, **p < 0.01, n.s. = not significant. The 
relative blood glucose concentration as a function of time after the tail vein injection of free insulin, PEG-
insulin, or PCB-insulin (C) before and (D) after purifying insulin conjugate products. The data are 
presented as the percentage of the initial values of blood glucose concentration ± standard deviation 
(n=6).  
 
A 
C 
D 
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Sample 
-
helix 
-structure 
(-turn and -
sheet) 
Random coil 
Free insulin 50% 26% 24% 
PEG-insulin 46% 24% 30% 
PCB-insulin 53% 24% 23% 
Table 4-2: The secondary structure proportion of insulin samples measured from Circular 
Dichroism (CD) Spectroscopy 
 
 
 
Figure 4-4: MALDI-TOF Mass spectra of native insulin, purified PEG-insulin and purified PCB-insulin 
where most of the three amines of insulin were conjugated with PEG or PCB.  
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Figure 4-5: (A) The bioactivity of native insulin, rough PEG-insulin, purified PEG-insulin, rough PCB-
insulin and purified PCB-insulin, respectively, as measured by phosphorylation of the insulin receptor in 
vitro.  For the polymer-insulin tested, most of the three amines of insulin were conjugated with PEG or 
PCB.  The relative activity was presented as the percentage of native insulin (n=6). *** p < 0.001. (B) 
The relative blood glucose concentration as a function of time after the tail vein injection of free insulin, 
rough PEG-insulin, and rough PCB-insulin (before purifying insulin conjugate products). The data are 
presented as the percentage of the initial values of blood glucose concentration ± standard deviation (n=6). 
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CHAPTER 5. CONCLUSION 
The focus of this thesis is the potential of the zwitterionic PCBs for drug delivery 
applications, including constructing micelles for chemo drug delivery and modifying glucose 
regulating proteins. Specifically, this thesis involves the discovery of the ultra-low CMC 
property of DSPE-PCB 5K micelle and the enhanced therapeutic performance of 
docetaxel/DSPE-PCB 5K formulation. In addition, zwitterionic PCB was used to conjugate with 
insulin and was found to be able to mitigate the long-lasting bioactivity loss problem when 
proteins were modified with current polymers.  
Compared with common conventional micelles, DSPE-PCB 5K showed ultra-low CMC 
property and high colloid stability in clinically relevant conditions. Such stabilizing effect 
appeared to be powerful; It was found that even when a zwitterionic moiety or polymer was 
added into a micelle solution (not chemically modifying the micelle), the existing micelle 
molecules in the new solution was stabilized at a concentration below its inherent CMC. It is 
further demonstrated that the ultra-low CMC micelle could stabilize hydrophobic cargo (without 
micelle dissociation) in diluted conditions and the findings reported here are expected to help the 
design of other micelle-based formulations to improve their stability. Using a melanoma tumor 
model, docetaxel/DSPE-PCB 5K formulation showed excellent anti-tumor performance by 
eliminating tumors in mice without a sign of recurrence. It is expected that the novel micelle 
system demonstrated here can encapsulate other commercially available chemo drugs and further 
promoted their therapeutic performance compared with their current micellar formulations.  
 Polymer-protein conjugation suffered from the bioactivity loss of protein since it was 
developed. It was found that PCB-insulin conjugation via simple one-step coupling chemistry 
does not compromise the bioactivity of insulin as confirmed in the in vitro test. In vivo study 
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indicated enhanced blood circulation time of the PCB-insulin conjugate. Combined with the 
advantage of improved pharmacokinetics and the prevention of bioactivity loss, PCB-insulin 
showed better glucose regulation effects in vivo compared with PEGylated insulin and 
unmodified natural insulin. This finding is likely to inspired future highly effective polymer-
protein conjugates to be developed.  
In the future, it is of interest to further explore the application of zwitterionic polymer in 
the drug delivery field based on these two projects. For the ultralow CMC micelle work, it will 
be of interest to test the encapsulation of other hydrophobic drugs and study anti-tumor 
performance in other types of cancer models. Further, the scale-up issue of producing ultralow 
zwitterionic micelles requires investigation for potential future commercialization and clinical 
trials. For the polymer-protein conjugation work, we are eager to know the mitigation of 
bioactivity loss of the modified protein can work on other types of therapeutic proteins. This will 
invovle similar studies to this dissertation by conjugating PCB to a few protein drugs of high 
therapeutic value and measuring the bioactivity of the protein after conjugation. 
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This dissertation focuses on the applications of zwitterionic polymer materials in drug 
delivery. In one project, zwitterionic polymers were used to construct micelle surfactants. The 
zwitterionic micelles were found to have an ultralow (< 2.7 × 10-6 mM) critical micelle 
concentration (CMC) and a potential mechanism for zwitterionic micelles achieving the ultralow 
CMC property has been studied. Based on the ultralow CMC feature, zwitterionic micelles were 
used to prepare a formulation of commercial antitumor drug docetaxel, and the resulting 
formulation showed excellent antitumor performance.  In another project, zwitterionic polymers 
were used to modify the protein drug insulin via conjugation reaction. Compared with current 
protein modification methods, such as PEGylation, zwitterionic polymer conjugation increased 
24% pharmacological activity compared with native insulin without compromising bioactivity.  
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